

# Effect of Norovirus Inoculum Dose on Virus Kinetics, Shedding, and Symptoms

Yang Ge, W. Zane Billings, Antone Opekun, Mary Estes, David Graham, Juan Leon, Katia Koelle, Ye Shen, Robert Atmar, Benjamin Lopman, Andreas Handel

The effect of norovirus dose on outcomes such as virus shedding and symptoms after initial infection is not well understood. We performed a secondary analysis of a human challenge study by using Bayesian mixed-effects models. As the dose increased from 4.8 to 4,800 reverse transcription PCR units, the total amount of shed virus in feces increased from  $4.5 \times 10^{11}$  to  $3.4 \times 10^{12}$  genomic equivalent copies; in vomit, virus increased from  $6.4 \times 10^5$  to  $3.0 \times 10^7$  genomic equivalent copies. Onset time of viral shedding in feces decreased from 1.4 to 0.8 days, and time of peak viral shedding decreased from 2.3 to 1.5 days. Time to symptom onset decreased from 1.5 to 0.8 days. One type of symptom score increased. An increase in norovirus dose was associated with more rapid shedding and symptom onset and possibly increased severity. However, the effect on virus load and shedding was inconclusive.

Norovirus is a major cause of foodborne disease and causes a large number of cases, hospitalizations, and deaths in the United States and globally (1–4). Specific treatments are not available, and vaccines are still under development (4,5). Generic infection control measures are the best approaches to minimizing disease burden (6–10).

An increase in exposure dose (number of virus particles) is associated with an increased risk for infection; this principle applies to norovirus (11–14) and many other pathogens (15,16). Less is known about the possible effect of dose on infection outcomes after

infection has occurred. For acute infections such as influenza, infectious bronchitis virus, and parainfluenza virus, animal studies and models suggest that dose influences the virus load kinetics (17–19). For norovirus, some evidence from experimental challenge studies suggests that dose is associated with more rapid onset of symptoms (20). To further elucidate the effect of inoculum dose on infection outcomes such as virus shedding and symptom severity, we performed a secondary analysis of data from a human norovirus challenge study (20).

## Methods

In this article, we will give brief descriptions of our methods. We have also provided complete modeling and analysis details, including all data and code needed to reproduce our results (Appendix, <https://wwwnc.cdc.gov/EID/article/29/7/23-0117-App1.pdf>).

## Data

The data we used for our analyses are from a human challenge study registered at ClinicalTrials.gov (trial no. NCT00138476) (20–24). The clinical protocol was reviewed and approved by the institutional review boards of the Baylor College of Medicine and The Houston Methodist Hospital, and written informed consent was obtained from each study participant.

In the challenge study, 57 healthy persons (18–50 years of age) were randomly inoculated with either placebo or norovirus genogroup I genotype 1 strain (GI.1 NV) at 4 different doses (0.48, 4.8, 48, or 4,800 reverse transcription PCR [RT-PCR] units). Of the 21 persons who became infected, 1 person was unavailable for follow-up, and thus we excluded that patient from all analyses. In addition, only 1 person in the 0.48-unit dose group became infected, so we excluded this person from our main analyses. Therefore, remaining for our analysis were 6 persons in the

---

Authors affiliations: University of Southern Mississippi School of Health Professions, Hattiesburg, Mississippi, USA (Y. Ge); University of Georgia, Athens, Georgia, USA (W.Z. Billings, Y. Shen, A. Handel); Baylor College of Medicine, Houston, Texas, USA (A. Opekun, M. Estes, D. Graham, R. Atmar); Emory University Rollins School of Public Health, Atlanta, Georgia, USA (J. Leon, B. Lopman); Emory University, Atlanta (K. Koelle)

DOI: <https://doi.org/10.3201/eid2907.230117>

4.8-unit dose group, 7 persons in the 4.8-unit dose group, and 6 persons in the 4,800-unit dose group. We provide analyses that include the 1 person who was infected at the 0.48-dose level (Appendix).

All persons were isolated in the research center for  $\geq 4$  days (96 hours) after inoculation. The study personnel collected samples of feces and vomit and recorded clinical symptoms.; samples were also collected for 4–8 weeks postinoculation. For some of our analyses, we focused on the 96 hours during which persons were under clinical observation. For other analyses, we included the data collected after persons returned home. We state which data are used for each analysis.

### Overall Analysis Approach and Implementation

Because we performed a secondary data analysis, a strict null hypothesis significance testing framework using *p* values was not suitable, so we performed all analyses in a Bayesian framework. For all analyses, we used Bayesian mixed-effects models. We treated the dose as a continuous variable for the results shown in the article. We also provide a sensitivity analysis with dose modeled as categorical (Appendix). We report the mean of the estimated posterior distribution with 95% equal-tailed credible intervals (CrIs) for all model results (25). We conducted all analyses using R version 4.2.3 (26), and Stan (27), accessed through the brms package in R (28). We used Rhat values to diagnose convergence (28).

### Analysis of Virus Shedding Outcomes

We measured virus shedding concentration in samples by either an immunomagnetic capture (IMC) RT-PCR, which provided a qualitative readout (positive or negative), or real-time quantitative RT-PCR (qRT-PCR), which provided a quantitative readout in genomic equivalent copies (GEC) (21). Those 2 methods had limits of detection (LOD) at 15,000 GEC/g of stool (LOD1) and 40,000,000 GEC/g of stool (LOD2). Therefore, the virus shedding concentration could be between 0 and LOD1 (negative IMC, negative qRT-PCR), between LOD1 and LOD2 (positive IMC, negative qRT-PCR), or a quantitative measurement above LOD2 (positive qRT-PCR). We reported vomit shedding data similarly, with either a numeric value or a positive or negative readout. We accounted for this censored data structure in our models (Appendix).

We obtained the total virus contained in each sample by multiplying virus concentration by sample weight for feces (GEC/g  $\times$  weight of feces in grams) or sample volume for vomit (GEC/mL  $\times$  volume of vomit in mL). We calculated each participant's total amount of virus shedding in feces and vomit by

summing virus shedding values for all samples per participant. We used a linear model structure to analyze associations between inoculum dose and the total amount of virus shedding.

In a further analysis, we modeled the longitudinal time-series of virus concentration in feces,  $V(t)$ , using the 4-parameter equation

$$V(t) = \frac{2p}{\exp(-g(t - T)) + \exp(d(t - T))}$$

which was shown to accurately describe trajectories of acute viral infections (17,29). We fitted the trajectories by using a Bayesian nonlinear mixed-effects model in which the mean of the response was described using this equation. We used the comparison between the parameter's prior and posterior distributions to ensure that the choice of prior distribution had no significant effect on our results. We sampled from the posterior distribution of the estimated parameters to obtain predicted trajectories of virus concentration kinetics. From those time-series, we computed several summary quantities: virus shedding onset (time at which the trajectory crossed LOD1); time to peak virus shedding; shedding duration, defined as the total amount of time at which virus concentration was above LOD1; and total amount of virus shed, defined as the area under the virus concentration curve.

Vomiting episodes were too few (11 persons with 26 samples of vomit) to enable a time-series analysis similar to the one we performed for virus shedding in feces. We have compiled vomit event time-series data (Appendix).

### Analysis of Symptom Outcomes

The study recorded 10 kinds of symptoms: body temperature, malaise, muscle aches, headache, nausea, chills, anorexia, cramps, unformed or liquid feces, and vomiting. Clinical symptom scores (except feces and vomit) were reported as none = 0, mild = 1, moderate = 2, or severe = 3. For feces, we used a scoring of solid = 0, unformed = 1, and liquid = 2. Vomit was reported as absent = 0 or present = 1.

We considered time to symptom onset (incubation period) and 2 symptom scores as outcomes of interest. We defined time to system onset as the time from inoculation to the first reported symptom of any type. For the first symptom score, we used a modified Vesikari score (MVS) that was previously applied to measure norovirus severity (5,30–33). We computed the MVS by using a limited number of symptoms (i.e., fever, diarrhea, and vomiting). We also developed an additional score, which we call the comprehensive symptom score (CSS), which encompasses all

**Table.** Selected characteristics of patients in study of the effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms\*

Characteristic	Dose, RT-PCR units			
	0.48	4.8	48	4,800
No. participants	1	6	7	6
Age, y, median (range)	24 (24–24)	30 (21–39)	24 (22–34)	28 (22–47)
Sex				
F	1 (100)	2 (33)	4 (57)	2 (33)
M	0	4 (67)	3 (43)	4 (67)
Blood type group				
A	0	2 (33)	2 (29)	3 (50)
O	1 (100)	4 (67)	5 (71)	3 (50)

\*Values are no. (%) except as indicated. RT-PCR, reverse transcription PCR.

reported 10 symptoms in this study. Additional details of score computation, scores for each individual, and further model details are provided (Appendix).

### Sensitivity Analyses

We performed 2 sensitivity analyses. In the first analysis, we treated dose as categorical rather than continuous. In the second analysis, we included 1 person who became infected after exposure to a dose of 0.48 RT-PCR units.

## Results

### Data Description

Detailed descriptions of the study can be found in previous publications (20–24). We summarized characteristics of the infected persons included in our analyses (Table). Distributions of age, sex, and ABO blood group status were generally similar across dose groups.

### Association between Dose and Total Virus Shedding

We computed total virus shedding in either feces or vomit by summing the amount of shed virus in all samples for each person. We focused on fecal shedding during the first 96 hours of the study, when patients were under clinical observation. Almost all viral shedding events that occurred during this timeframe were recorded. Every person shed virus in  $\geq 1$  fecal sample. All vomiting events occurred within the first 96 hours, and only 11 persons vomited. Virus shedding showed some association with dose, although with a fair amount of uncertainty (Figure 1), leading to overall inconclusive results. We developed an alternative analysis using fecal shedding that includes the self-reported data after persons returned to their homes (Appendix). In that case, we observed no noticeable association.

### Association between Dose and Viral Kinetics

Next, we fitted the virus concentration model to the time-series data for virus load for each person. The

parameter's prior and posterior distributions showed that the choice of prior distribution had no significant effect on our results (Appendix).


We calculated the population-level curves per dose group for the estimated virus load trajectories (Figure 2) and developed fitted curves for each person (Appendix). The curves show a trend toward more rapid onset and earlier virus peak as dose increases (Figure 2, panel B) but little effect on shedding duration and total viral load (Figure 2, panel A). To further quantify these results, we sampled trajectories from the posterior distributions. For each trajectory, we computed 4 quantities (indicated in Figure 2, panel A): shedding onset (i.e., time at which virus became detectable), time of peak virus shedding, duration of virus shedding, and the total amount of virus shed (computed as area under the curve). We then examined the distribution of each of these quantities.

We calculated the model-predicted relationship between dose and those 4 quantities (Figure 3). As the dose increased from 4.8 to 4,800 RT-PCR units, average onset time decreased from 1.4 (95% CrI 1.1–1.8) to 0.8 (95% CrI 0.5–1.1) days, and the time of virus peak decreased from 2.3 (95% CrI 2–2.8) to 1.5 (95% CrI 1.3–1.8) days. We observed a very slight trend toward increased duration of shedding, from 23.7 (95% CrI 17.8–30.6) to 26.4 (95% CrI 19–35.8) days. Total virus load barely changed, from  $1.5 \times 10^{10}$  (95% CrI  $2.2 \times 10^9$ – $5.2 \times 10^{10}$ ) to  $1.7 \times 10^{10}$  (95% CrI  $1.9 \times 10^9$ – $6.6 \times 10^{10}$ ) GEC  $\times$  days/g.

### Association between Dose and Symptoms

We investigated associations between dose and symptom related outcomes next. A higher inoculum dose was associated with a shorter incubation period (more rapid symptoms onset) (Figure 4). The incubation period decreased from 1.5 (95% CrI 0.9–2.5) to 0.8 (95% CrI 0.4–1.4) days as dose increased (Figure 4, panel A).

Our model estimated a slight increase in symptoms as measured by the MVS, from 2.9 (95% CrI 1.4–5.2) to 3.3 (95% CrI 1.4–6.5) as dose increased (Figure 4, panel B). The CSS showed a more pronounced



**Figure 1.** Total virus shedding in feces and vomit of patients challenged with norovirus in study of the effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms. A) Cumulative virus shedding in feces. B) Cumulative virus shedding in vomit. Open circles represent raw data points. Lines and shaded regions indicate means and 95% CrIs of the fitted Bayesian model. Missing values attributable to limits of detection were replaced with fixed values (Appendix, <https://wwwnc.cdc.gov/EID/article/29/7/23-0117-App1.pdf>). CrI, credible interval; GEC, genomic equivalent copies; RT-PCR, reverse transcription PCR.

increase, from 9.4 (95% CrI 6.1–13.6) to 18.7 (95% CrI 11.8–28.3) (Figure 4, panel C). A further analysis suggests that the different pattern seen for the MVS and CSS might be attributable to those symptoms that are part of the MVS not showing an association with dose, whereas a few symptoms (e.g., cramps, malaise, nausea) that are part of the CSS but not the MVS do show a correlation with dose (Appendix).


### Sensitivity Analyses


We performed 2 main sensitivity analyses (Appendix). In the first sensitivity analysis, we treated dose as categorical (low, medium, or high) instead of continuous. For this analysis, total virus shedding in feces and vomit was highest at the intermediate

dose, though with overlap of the credible intervals for all doses. Similar to results for the main analysis, an increase in dose led to earlier onset and peak of shedding. Duration of shedding and total virus load concentration also suggested the highest levels at intermediate doses, although again with overlap in uncertainty estimates. Symptom onset was earlier, and the CSS measure increased, with no noticeable effect on the MVS measure.

In the second sensitivity analysis, we included 1 person infected after receiving the lowest dose (0.48 RT-PCR units). For this dataset, we found similar patterns of increasing total virus shedding in feces and vomit as dose increased. Also consistent with those results, onset and peak of shedding occurred earlier

**Figure 2.** Fitted virus concentration (GEC/g) in feces of patients challenged with norovirus in study of the effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms. A) Fitted curves showing the full infection time-course. Onset is time at which virus load rose to the LOD1 level. Duration is amount of time where virus load was above the LOD1 level. Peak is time to virus peak shedding. B) Zoomed in plot of the first 7 days to better show the initial increase and peak. Curves and shaded regions indicate means and credible intervals of the fitted time series Bayesian model. LOD1 and LOD2 lines indicate the 2 different limits of detection. Missing values attributable to limits of detection were treated as censors (Appendix, <https://wwwnc.cdc.gov/EID/article/29/7/23-0117-App1.pdf>). AUC, area under virus concentration curve; GEC, genomic equivalent copies; LOD, limit of detection; RT-PCR, reverse transcription PCR.





**Figure 3.** Associations between 4 characteristics of fecal viral shedding kinetics and levels of inoculum dose in patients in study of the effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms. A) Shedding onset (time at which virus load reaches limit of detection 1). B) Time to virus peak shedding. C) Shedding duration (amount of time where virus load was above limit of detection 1). D) Total virus load (area under the fitted trajectory). Lines and shaded regions indicate means and 95% credible intervals of the posterior samples of the fitted time series model. RT-PCR, reverse transcription PCR.

but duration of shedding and total virus load concentration did not change noticeably. Symptom onset was earlier and stronger based on the CSS measure, with no noticeable effect on the MVS.

The categorical analysis suggested similar patterns but supported, albeit very tentatively, that intermediate dose might be associated with the highest level of shedding. However, because only a single person fell into the lowest-dose category, a categorical analysis that included that person did not seem to be useful, so we did not perform such an analysis.

In time series models, we treated values below the limits of detection as censors. In other virus shedding models, we additionally performed 2 sensitivity analyses to explore the effect of choices for the values that are below the limits of detection. The conclusions remained consistent (Appendix).


## Discussion

We explored the effect of norovirus inoculum dose on infection and disease outcomes, an important gap in the literature. We found that an increased dose was associated with a faster onset and peak of virus shedding in feces (Figure 3, panel A, B) but not with fecal shedding duration and total virus concentration (Figure 3, panel C, D). A trend toward increased total shedding was noted for both feces and vomit (Figure 1). Our analysis also showed a pattern of accelerated onset of symptoms. Symptom severity

showed an increase with inoculum dose for the CSS measure but not the MVS measure (Figure 4), possibly because only some symptoms are affected by dose, and those symptoms are captured by CSS but not MVS (Appendix). An increase in symptoms despite no noticeable change in virus load suggests that symptoms are mostly immune-mediated. We found mild evidence that a high virus growth rate associated with increased symptoms (Appendix); thus, a more rapid initial virus growth might trigger a stronger immune response. This finding could be tested in studies that measure components of the ensuing immune response.

Findings similar to ours have been reported for other enteric pathogens. The clinical manifestation of typhoid illness appears to be independent of inoculum dose, whereas the onset of symptoms was more rapid after a higher infectious dose (34). More rapid onset of symptoms after a larger infectious dose has also been observed with cholera infections (35). This finding could suggest a general pattern of dose-dependent incubation periods for enteric diseases. We did not find evidence of presymptomatic virus shedding, which could be attributable to the fact that diarrhea and vomit were considered as symptoms in our research, which explains the similar time of virus shedding onset time and incubation period.

The association between dose and severity might partially explain the results of several recent



**Figure 4.** Association between inoculum dose and symptoms in patients in study of the effect of norovirus inoculum dose on virus kinetics, shedding, and symptoms. A) Incubation period (i.e., time between infection and onset of first symptoms). B) Severity using the modified Vesikari score. C) Severity using the comprehensive symptom score. Circles show raw data for participants. Lines and shaded regions indicate means and 95% credible intervals of the fitted Bayesian model. RT-PCR, reverse transcription PCR.

norovirus vaccine candidates. Those vaccines have shown limited effectiveness at reducing the risk for infection but do seem to reduce disease outcomes (5,36). Perhaps protection induced by current vaccine candidates (assumed to be mainly mediated by antibodies) is not enough to provide sterilizing immunity and thus prevent infection but can reduce the effective dose that starts an infection and thereby reduce symptoms. This pattern would be consistent with our findings here.

However, it is unclear what the typical norovirus dose is for natural infections and how that dose compares with the doses chosen in the challenge study data we analyzed. This uncertainty limits any possibility to generalize results obtained from challenge studies to natural infections or the potential role of vaccine candidates at influencing the effective inoculum size that starts an infection. Thus, potential clinical or epidemiologic implications of changes in dose for natural infections will need to await further investigations to determine the potential applicability of challenge study results to such natural infection settings.

Our analysis was a secondary data analysis of a limited number of persons, which resulted in wide credible intervals and constrained further explorations of nonlinear models. The associations we found may not equal to causality. As such, our results should be considered exploratory and need to be confirmed in future studies. Further studies, ideally with larger sample sizes, are needed. Larger sample sizes might also allow for stratification on the basis of host characteristics, which could yield information regarding possible interactions between host characteristics and dose–outcome relationships.

In conclusion, if we can assume that the associations we found have an underlying causal relation (something that needs to be confirmed in future studies), our results suggest that norovirus dose might

affect some infection outcomes while not influencing others. Thus, when comparing results across challenge studies or trying to combine data from multiple studies for analysis, some care must be taken if doses are different. In some instances, combining data across studies seems reasonable, such as combining data from multiple studies to focus on viral shedding. However, for symptom-related outcomes and quantities that focus on norovirus infection kinetics, dose differences might lead to differences between studies that prohibit easy comparison.

Y.G., J.L., K.K., B.L., and A.H. are partially supported by National Institutes of Health grant no. R01 GM124280. Y.G. was supported by the Start-Up Grant from the University of Southern Mississippi. J.L. is partially supported by the National Institute of Food and Agriculture at the US Department of Agriculture (grant no. 2019-67017-29642). Z.B. is supported by the University of Georgia Graduate School. Y.S. is partially supported by National Institutes of Health grant no. R35 GM146612. D.G. and A.O. are partially supported by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service (grant no. DK56338), which funds the Texas Medical Center Digestive Diseases Center.

### About the Author

Dr. Ge is an assistant professor at the University of Southern Mississippi. His research focuses on infectious disease epidemiology, covering pathogens like influenza, norovirus, SARS-CoV-2, and tuberculosis.

### References

1. Patel MM, Widdowson M-A, Glass RI, Akazawa K, Vinjé J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. *Emerg Infect Dis*. 2008;14:1224–31. <https://doi.org/10.3201/eid1408.071114>

2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2095–128. [https://doi.org/10.1016/S0140-6736\(12\)61728-0](https://doi.org/10.1016/S0140-6736(12)61728-0)
3. Bartsch SM, Lopman BA, Ozawa S, Hall AJ, Lee BY. Global economic burden of norovirus gastroenteritis. *PLoS One*. 2016;11:e0151219. <https://doi.org/10.1371/journal.pone.0151219>
4. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. *Emerg Infect Dis*. 2011;17:7–15. <https://doi.org/10.3201/eid1701.P111101>
5. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk virus illness. *N Engl J Med*. 2011;365:2178–87. <https://doi.org/10.1056/NEJMoa1101245>
6. Johnston CP, Qiu H, Ticehurst JR, Dickson C, Rosenbaum P, Lawson P, et al. Outbreak management and implications of a nosocomial norovirus outbreak. *Clin Infect Dis*. 2007;45:534–40. <https://doi.org/10.1086/520666>
7. Isakbaeva ET, Widdowson M-A, Beard RS, Bulens SN, Mullins J, Monroe SS, et al. Norovirus transmission on cruise ship. *Emerg Infect Dis*. 2005;11:154–8. <https://doi.org/10.3201/eid1101.040434>
8. Carling PC, Bruno-Murtha LA, Griffiths JK. Cruise ship environmental hygiene and the risk of norovirus infection outbreaks: an objective assessment of 56 vessels over 3 years. *Clin Infect Dis*. 2009;49:1312–7. *PMID 19814610*
9. Wikswo ME, Cortes J, Hall AJ, et al. Disease transmission and passenger behaviors during a high morbidity norovirus outbreak on a cruise ship, January 2009. *Clin Infect Dis*. 2011;52:1116–22. *PMID 21429864*
10. Bitler EJ, Matthews JE, Dickey BW, Eisenberg JNS, Leon JS. Norovirus outbreaks: a systematic review of commonly implicated transmission routes and vehicles. *Epidemiol Infect*. 2013;141:1563–71. *PMID 23433247*
11. Teunis PFM, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how infectious is it? *J Med Virol*. 2008;80:1468–76. <https://doi.org/10.1002/jmv.21237>
12. Van Abel N, Schoen ME, Kissel JC, Meschke JS. Comparison of risk predicted by multiple norovirus dose-response models and implications for quantitative microbial risk assessment. *Risk Anal*. 2017;37:245–64. <https://doi.org/10.1111/risa.12616>
13. Messner MJ, Berger P, Nappier SP. Fractional Poisson—a simple dose-response model for human norovirus. *Risk Anal*. 2014;34:1820–9. <https://doi.org/10.1111/risa.12207>
14. Schmidt PJ. Norovirus dose-response: are currently available data informative enough to determine how susceptible humans are to infection from a single virus? *Risk Anal*. 2015;35:1364–83. <https://doi.org/10.1111/risa.12323>
15. Haas CN. Estimation of risk due to low doses of microorganisms: a comparison of alternative methodologies. *Am J Epidemiol*. 1983;118:573–82. <https://doi.org/10.1093/oxfordjournals.aje.a113662>
16. Teunis PFM, Nagelkerke NJD, Haas CN. Dose response models for infectious gastroenteritis. *Risk Anal*. 1999;19:1251–60. <https://doi.org/10.1111/j.1539-6924.1999.tb01143.x>
17. Li Y, Handel A. Modeling inoculum dose dependent patterns of acute virus infections. *J Theor Biol*. 2014;347:63–73. <https://doi.org/10.1016/j.jtbi.2014.01.008>
18. Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. *PLoS Comput Biol*. 2018;14:e1006505. *PMID 30273336*
19. Moore JR, Ahmed H, Manicassamy B, Garcia-Sastre A, Handel A, Antia R. Varying inoculum dose to assess the roles of the immune response and target cell depletion by the pathogen in control of acute viral infections. *Bull Math Biol*. 2020;82:35. <https://doi.org/10.1007/s11538-020-00711-4>
20. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Determination of the 50% human infectious dose for Norwalk virus. *J Infect Dis*. 2014;209:1016–22. <https://doi.org/10.1093/infdis/jit620>
21. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Norwalk virus shedding after experimental human infection. *Emerg Infect Dis*. 2008;14:1553–7. <https://doi.org/10.3201/eid1410.080117>
22. Kavanagh O, Estes MK, Reeck A, Raju RM, Opekun AR, Gilger MA, et al. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. *Clin Vaccine Immunol*. 2011;18:1187–90. <https://doi.org/10.1128/CVI.00039-11>
23. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. *Clin Vaccine Immunol*. 2012;19:284–7. <https://doi.org/10.1128/CVI.05592-11>
24. Ajami NJ, Barry MA, Carrillo B, Muhaxhiri Z, Neill FH, Prasad BV, et al. Antibody responses to norovirus genogroup GI.1 and GI.4 proteases in volunteers administered Norwalk virus. *Clin Vaccine Immunol*. 2012;19:1980–3. <https://doi.org/10.1128/CVI.00411-12>
25. McElreath R. Statistical rethinking: a Bayesian course with examples in R and Stan. 2nd edition. Boca Raton: Taylor and Francis, CRC Press; 2020.
26. R Core Team. R: a language and environment for statistical computing. 2017 [cited 2023 Apr 22]. <https://www.r-project.org>
27. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: a probabilistic programming language. *J Stat Softw*. 2017;76:1–32.
28. Burkner P-C. Brms: an R Package for Bayesian multilevel models using Stan. *J Stat Softw*. 2017;80. <https://doi.org/10.18637/jss.v080.i01>
29. Holder BP, Beauchemin CA. Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture. *BMC Public Health*. 2011;11(Suppl 1):S10. <https://doi.org/10.1186/1471-2458-11-S1-S10>
30. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scand J Infect Dis*. 1990;22:259–67. <https://doi.org/10.3109/00365549009027046>
31. Freedman SB, Eltorky M, Gorelick M; Pediatric Emergency Research Canada Gastroenteritis Study Group. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics*. 2010;125:e1278–85. <https://doi.org/10.1542/peds.2009-3270>
32. Bierhoff M, Arvelo W, Estevez A, Bryan J, McCracken JP, López MR, et al. Incidence and clinical profile of norovirus disease in Guatemala, 2008–2013. *Clin Infect Dis*. 2018;67:430–6. <https://doi.org/10.1093/cid/ciy091>
33. Shim DH, Kim DY, Cho KY. Diagnostic value of the Vesikari scoring system for predicting the viral or bacterial pathogens in pediatric gastroenteritis. *Korean J Pediatr*. 2016;59:126–31. <https://doi.org/10.3345/kjp.2016.59.3.126>

34. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. *N Engl J Med*. 1970;283:686–91. <https://doi.org/10.1056/NEJM197009242831306>
35. Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ, et al. The Broad Street pump revisited: response of volunteers to ingested Cholera vibrios. *Bull N Y Acad Med*. 1971;47:1181–91.
36. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, et al. Norovirus vaccine against experimental


human GII.4 virus illness: a challenge study in healthy adults. *J Infect Dis*. 2015;211:870–8. <https://doi.org/10.1093/infdis/jiu497>

Address for correspondence: Yang Ge, 118 College Dr, School of Health Professions, University of Southern Mississippi, Hattiesburg, MS 39402, USA; email: yang.ge@usm.edu; or Andreas Handel, 124 B.S. Miller Hall, Health Sciences Campus, University of Georgia, Athens, GA 30602, USA; email: ahandel@uga.edu

May 2023

## Bacterial Infections

- Trends in and Risk Factors for Recurrent *Clostridioides difficile* Infection, New Haven County, Connecticut, USA, 2015–2020
- Phylogenetic Analysis of Transmission Dynamics of Dengue in Large and Small Population Centers, Northern Ecuador
- Emergence of Erythromycin-Resistant Invasive Group A *Streptococcus*, West Virginia, USA, 2020–2021
- Environmental, Occupational, and Demographic Risk Factors for Clinical Scrub Typhus, Bhutan
- Misdiagnosis of *Clostridioides difficile* Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019–2020
- SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
- Disparities in Implementing COVID-19 Prevention Strategies in Public Schools, United States, 2021–22 School Year
- *Leishmania donovani* Transmission Cycle Associated with Human Infection, *Phlebotomus alexandri* Sand Flies, and Hare Blood Meals, Israel
- Case–Control Study of Long COVID, Sapporo, Japan
- Influence of Sex and Sex-Based Disparities on Prevalent Tuberculosis, Vietnam, 2017–2018 [
- Use of High-Resolution Geospatial and Genomic Data to Characterize Recent Tuberculosis Transmission, Botswana
- Spatiotemporal Evolution of SARS-CoV-2 Alpha and Delta Variants during Large Nationwide Outbreak of COVID-19, Vietnam, 2021



- Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
- Mpox among Public Festival Attendees, Chicago, Illinois, USA, July–August 2022
- Severe *Streptococcus equi* Subspecies *zooepidemicus* Outbreak from Unpasteurized Dairy Product Consumption, Italy
- Characteristics and Treatment of *Gordonia* spp. Bacteremia, France
- No Substantial Histopathologic Changes in *Mops condylurus* Bats Naturally Infected with Bombali Virus, Kenya
- Comparative Aerosol and Surface Stability of SARS-CoV-2 Variants of Concern
- Poor Prognosis for Puumala Virus Infections Predicted by Lymphopenia and Dyspnea
- Rustrela Virus as Putative Cause of Nonsuppurative Meningoencephalitis in Lions
- Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova
- Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022
- *Burkholderia pseudomallei* Laboratory Exposure, Arizona, USA
- Epizootic Hemorrhagic Disease Virus Serotype 8, Italy, 2022
- Human-to-Animal Transmission of SARS-CoV-2, South Korea, 2021
- Norovirus GII.3[P25] in Patients and Produce, Chanthaburi Province, Thailand, 2022
- COVID-19 Vaccine Uptake by Infection Status in New South Wales, Australia
- Emerging Invasive Group A *Streptococcus* M1UK Lineage Detected by Allele-Specific PCR, England, 2020
- Cutaneous Leishmaniasis Caused by *Leishmania infantum*, Israel, 2018–2021
- Fatal Case of Heartland Virus Disease Acquired in the Mid-Atlantic Region, United States
- Case Report and Literature Review of Occupational Transmission of Monkeypox Virus to Healthcare Workers, South Korea
- *Borrelia miyamotoi* Infection in Immunocompromised Man, California, USA, 2021
- Novel Circovirus in Blood from Intravenous Drug Users, Yunnan, China
- Cystic Echinococcosis in Northern New Hampshire, USA

**EMERGING  
INFECTIOUS DISEASES**

To revisit the May 2023 issue, go to:  
<https://wwwnc.cdc.gov/eid/articles/issue/29/5/table-of-contents>



# Effect of Norovirus Inoculum Dose on Virus Kinetics, Shedding, and Symptoms

## Appendix

### Overview

This document contains detailed model description, additional results, and instruction in reproducibility. We also provided a separate folder contains all materials for reproducibility (<https://github.com/yangepigroup/eid230117>).

### Code and data files to reproduce results

#### Main files

The 1\_manuscript folder contains the RMarkdown file of the main manuscript (manuscript\_main\_text.rmd) and auxiliary files (the template.docx help set font size, font family and so on). The 2\_supplementary\_materials folder contains supplementary\_text.rmd (the RMarkdown file of the supplement, which produces this document), a data folder, which contains the data (norodata.rds), an analyses folder, which contains all R codes for data analysis, and a common\_functions folder, which contains several functions used by the scripts in the the analyses folder.

#### Data file

The norodata.Rds (R data file (Rds)) contains a list with nine elements (Appendix Table 1). Each element contains parts of the data formatted in a way that is suitable for its intended analysis. These datasets were used by the R scripts in the analyses folder.

Data fvshed\_gmu\_96h\_LOD12\_0\_15000 and fvshed\_gmu\_96h\_LOD12\_0\_4e7 related to sensitivity analyses of limit detection issues that described in later sections.

The variables show in Appendix Table 2 are shared across all data subsets.

The dataset of `ftsshedding` (fecal virus shedding) has several variables necessary for later time-series modeling (Appendix Table 3).

The dataset of `css_10symptoms` has ten kinds of symptoms collected from the trial. The dataset of `css` has a variable (`css`) for comprehensive symptom score (CSS). The dataset of `mvs` has one variable (`mvs`) for the Modified Vesikari score (MVS), and five variables (`mvs1` to `mvs5`) for five score components, respectively.

### **Analysis files**

The `analyses` folder contains all R code for data analysis. For different outcomes, there is always one script that performs the model fitting (`<OUTCOME>.R`), and one for generating figures (`<OUTCOME>_plot.R`). Readers should choose an outcome and run the modeling code first, and then execute the plotting code. These are the existing scripts for fitting the different outcomes:

- `allshedding_con.R` fits models to the 3 total shedding outcomes, treating dose as continuous. The code fits models for both the 19 individuals shown in the main text, and the 20 individuals shown in the supplementary results.
- `allshedding_cat.R` fits models to the 3 total shedding outcomes, treating dose as categorical.
- `tsshedding_con.R` and `tsshedding_cat.R` fit the time-series data for fecal shedding to models, treating dose either continuous or categorical, respectively.

`allsymptoms_con.R` and `allsymptoms_cat.R` fit the incubation period, CSS, and MVS outcomes for continuous or categorical dose, respectively.

Model results are saved in the `/results/rds/`, and figures are saved in the `/results/plots/`.

### **Reproducing results**

To reproduce all our analyses, please follow these steps:

1. Double click `norovirus.Rproj`.
2. Install necessary packages, including `knitr`, `dplyr`, `tidyr`, `here`, `brms`, `huxtable`, `ggplot2`, `patchwork`, `stringr`, `ggthemes`, `ggpubr`.
3. Open and run the R script `allshedding_con.R`, and then `allshedding_con_plot.R`.

4. Open and run the R script `allsymptoms_con.R`, and then `allsymptoms_con_plot.R`.
5. Open and run the R script `allshedding_cat.R`, and then `allshedding_cat_plot.R`.
6. Open and run the R script `allsymptoms_cat.R`, and then `allsymptoms_cat_plot.R`.
7. Open and run the R script `tshedding_con.R`, and then `tshedding_con_plot.R`.
8. Open and run the R script `tshedding_cat.R`, and then `tshedding_cat_plot.R`.
9. Open and run the RMD script `manuscript_main_text.rmd`, and `supplementary_text.rmd`.

In our Bayesian models, we implemented four chains with four CPU cores. Depending on the computer performance, models may need a few hours to run.

### **Analysis with rethinking package**

All results presented in the main text and supplement are fit using Stan through the `brms` R package. As a check, we also implemented the same models with the `rethinking` package, which provides another R interface to the Stan fitting software.

The code for the models implemented with `rethinking` is in the folder `2_supplementary_materials/analyses/rethinking-analysis` folder.

To run these scripts, the `rethinking` R package will need to be installed following the instructions here: <https://github.com/rmcelreath/rethinking>

The folder contains three scripts which must be run in the following order:

1. Open and run the R script `models.R`. This script fits the models to the data and consequently will have a long run time.
2. Open and run the R script `preds.R`. This script processes the Stan model objects and generates the model predictions of interest. Some steps, particularly processing the time series models, may have a long run time.
3. Open and run the R script `figs.R`. This script generates replicate figures similar to those included in the manuscript and the supplement.

All of the results (model objects, predictions, and figures) will be saved in the folder `2_supplementary_materials/analyses/rethinking-results`. If this folder and the necessary

subfolders do not exist, they will be created for you the first time the script models.R is run. Finally, we recommend restarting the R session between scripts to ensure that sufficient memory is available.

### Session information

We provide our PC session information as below:

```
## R version 4.2.3 (2023-03-15 ucrt)
## Platform: x86_64-w64-mingw32/x64 (64-bit)
## Running under: Windows 10 x64 (build 19045)
##
## Matrix products: default
##
## locale:
## [1] LC_COLLATE = English_United States.utf8
## [2] LC_CTYPE = English_United States.utf8
## [3] LC_MONETARY = English_United States.utf8
## [4] LC_NUMERIC = C
## [5] LC_TIME = English_United States.utf8
##
## attached base packages:
## [1] parallel stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] ggpubr_0.6.0 rethinking_2.31 cmdstanr_0.5.3
## [4] rstan_2.26.21 StanHeaders_2.26.21 ggthemes_4.2.4
## [7] stringr_1.5.0 patchwork_1.1.2 ggplot2_3.4.2
## [10] fitExtra_0.5.0 huxtable_5.5.2 brms_2.19.0
## [13] Rcpp_1.0.10 here_1.0.1 tidyr_1.3.0
## [16] dplyr_1.1.1 knitr_1.42
##
## loaded via a namespace [and not attached]:
```

## [1] uuid\_1.1-0 backports\_1.4.1 systemfonts\_1.0.4  
## [4] plyr\_1.8.8 igraph\_1.4.1 crosstalk\_1.2.0  
## [7] rstantools\_2.3.1 inline\_0.3.19 digest\_0.6.31  
## [10] htmltools\_0.5.5 fansi\_1.0.4 magrittr\_2.0.3  
## [13] checkmate\_2.1.0 RcppParallel\_5.1.7 matrixStats\_0.63.0  
## [16] officer\_0.6.2 xts\_0.13.0 askpass\_1.1  
## [19] gfonts\_0.2.0 prettyunits\_1.1.1 colorspace\_2.1-0  
## [22] textshaping\_0.3.6 xfun\_0.38 callr\_3.7.3  
## [25] crayon\_1.5.2 jsonlite\_1.8.4 zoo\_1.8-11  
## [28] glue\_1.6.2 gtable\_0.3.3 V8\_4.2.2  
## [31] distributional\_0.3.2 car\_3.1-2 pkgbuild\_1.4.0  
## [34] shape\_1.4.6 abind\_1.4-5 scales\_1.2.1  
## [37] fontquiver\_0.2.1 mvtnorm\_1.1-3 rstatix\_0.7.2  
## [40] miniUI\_0.1.1.1 xtable\_1.8-4 stats4\_4.2.3  
## [43] fontLiberation\_0.1.0 DT\_0.27 htmlwidgets\_1.6.2  
## [46] threejs\_0.3.3 posterior\_1.4.1 ellipsis\_0.3.2  
## [49] pkgconfig\_2.0.3 loo\_2.6.0 farver\_2.1.1  
## [52] utf8\_1.2.3 crul\_1.3 tidyselect\_1.2.0  
## [55] rlang\_1.1.0 reshape2\_1.4.4 later\_1.3.0  
## [58] munsell\_0.5.0 tools\_4.2.3 cli\_3.6.1  
## [61] generics\_0.1.3 broom\_1.0.4 evaluate\_0.20  
## [64] fastmap\_1.1.1 yaml\_2.3.7 ragg\_1.2.5  
## [67] processx\_3.8.0 zip\_2.2.2 purrr\_1.0.1  
## [70] nlme\_3.1-162 mime\_0.12 xml2\_1.3.3  
## [73] compiler\_4.2.3 bayesplot\_1.10.0 shinythemes\_1.2.0  
## [76] rstudioapi\_0.14 curl\_5.0.0 ggsignif\_0.6.4  
## [79] tibble\_3.2.1 stringi\_1.7.12 ps\_1.7.4  
## [82] Brodningnag\_1.2-9 gdtools\_0.3.3 lattice\_0.20-45  
## [85] Matrix\_1.5-3 fontBitstreamVera\_0.1.1 markdown\_1.5  
## [88] shinyjs\_2.1.0 tensorA\_0.36.2 vctrs\_0.6.1  
## [91] pillar\_1.9.0 lifecycle\_1.0.3 bridgesampling\_1.1-2

```
## [94] data.table_1.14.8 flextable_0.9.1 httpuv_1.6.9
## [97] R6_2.5.1 bookdown_0.33 promises_1.2.0.1
## [100] gridExtra_2.3 codetools_0.2-19 colourpicker_1.2.0
## [103] MASS_7.3-58.2 gtools_3.9.4 assertthat_0.2.1
## [106] openssl_2.0.6 rprojroot_2.0.3 withr_2.5.0
## [109] httpcode_0.3.0 shinystan_2.6.0 grid_4.2.3
## [112] coda_0.19-4 rmarkdown_2.21 carData_3.0-5
## [115] shiny_1.7.4 base64enc_0.1-3 dygraphs_1.1.1.6
```

## **Analysis of virus shedding**

The following sections provide additional details and further results related to our analyses of virus shedding.

### **Accounting for limits of detection in virus shedding**

The study that produced the data used two different methods to determine virus concentration in feces (*I*). The first method was a quantitative real-time RT-PCR (qRT-PCR) method. This method was able to detect virus up to a limit of detection of  $40 \times 10^6$  genomic equivalent copies (GEC). If a sample was below this level (negative qPCR reading), the sample was retested using an immunomagnetic capture (IMC) RT-PCR assay. IMC RT-PCR is more sensitive, with a lower limit of detection of  $15 \times 10^3$  GEC, but only produces a qualitative positive or negative readout. We labeled the limit of  $15 \times 10^3$  GEC as LOD1, and  $40 \times 10^6$  as LOD2. Thus, virus samples have a numeric value if they are above LOD2, are labeled as positive if they are below LOD2 but above LOD1, and are labeled as negative if they are below LOD1.

We dealt with these detection limits as follows.

For the analyses involving the time-series data of fecal virus shedding in our Bayesian nonlinear mixed effects model, we used the built-in approach of brms to handle censored values and deal with the limits of detection (2). In the time series models, the missing data were considered as censors. For example, with two LODs, 1) If the data was below both LODs (-,-), the interval was between 1 and 15000 (which leads to 0 and  $\log(15000)$  on the modeling scale). 2) If the data was (+,-), the interval was between 15000 and  $4e7$ ; 3) If the data was (+,+), instead

of interval, the observed value was used. In brms, the likelihood function uses a cumulative distribution function for censored data (3).

For the simple analysis that does not use the time-series model, we substituted values. If a sample had a quantitative concentration above  $40 \times 10^6$  GEC, we used the numeric value. If a sample was reported as positive (concentration between  $40 \times 10^6$  GEC and  $15 \times 10^3$  GEC), we used the geometric mean of those two values ( $\approx 7.75 \times 10^5$  GEC). Similarly, if a sample was recorded as negative (concentration below  $15 \times 10^3$  GEC), we used the geometric mean of  $15 \times 10^3$  GEC and 1 GEC ( $\approx 122$  GEC). To explore the impact of these choices, we additionally performed two sensitivity analyses. We set values below the LOD1 to 1, and values between LOD1 and LOD2 were set to either 15000 (the LOD1 value) or  $4e7$  (the LOD2 value), to explore two extremes. These additional analyses are shown further below in this supplement.

To compute the total amount of virus shed per shedding event, we multiplied the virus concentration with the weight of the shed feces (i.e., GEC/g  $\times$  weight of feces). Finally, for each individual, we summed values for all shedding events.

Data for vomiting had similar limits of detection. These data were recorded as either a numeric value above 2,200 GEC, a positive readout below 2,200 GEC or a negative readout. For the vomiting data, we did not have information on the limit of detection for the qualitative assay. Based on a comparison of the two methods (4), we made the assumption that the LOD for the qualitative assay was a factor of 10 lower, thus 220 GEC. We then again took the geometric mean of 2,200 GEC and 220 GEC for the positive values ( $\approx 696$  GEC), and 220 GEC and 1 GEC for the negative values ( $\approx 15$  GEC). All virus concentrations were then multiplied with total vomit volume (i.e., virus particles/ml  $\times$  volume of vomit), then summed those for each individual. This included making the additional assumption that 1 g of vomit equated to 1 mL (5).

### **Modeling total virus shedding**

We computed total virus shedding by multiplying virus concentration with sample weight (feces) or volume (vomit) for each shedding event, and summing all values for each individual.

We applied a mixed effects model that investigated associations between the outcomes (total shedding amount) and inoculum dose. For the analysis shown in the main text, we assumed a linear relationship between the log of the dose ( $x_i$ ) and the log of the outcome ( $y_i$ ).

We fitted the same model to each of the 3 outcomes. Those are 1) fecal shedding during the 96 hours under clinical observation, 2) fecal shedding including the time at which individuals recorded shedding events at home, and 3) vomit shedding (which occurred only during the first 96 hours).

The mathematical definition of the model is as follows:

Likelihood:	$y_i \sim \text{Normal}(\mu_i, \sigma)$
Linear model:	$\mu_i = \alpha_i + \beta(x_i - x^*)$
Adaptive priors:	$\alpha_i \sim \text{Normal}(\delta, \gamma)$
Fixed priors:	$\delta \sim \text{Normal}(25, 5)$ $\gamma \sim \text{Half-Cauchy}(0, 2)$ $\beta \sim \text{Normal}(0, 1)$ $\sigma \sim \text{Half-Cauchy}(0, 2)$

The outcome of interest,  $y_i$ , is the total amount of virus shedding (in log units) of individual  $i$ . We assumed this value to be normally distributed with mean,  $\mu_i$ , and an overall standard deviation,  $\sigma$ . The mean was assumed to have an individual-specific component and a dose-dependent component. The parameter  $\alpha_i$  describes the individual-level, dose-independent expected mean of the outcome for each individual, the parameter  $\beta$  encodes the potential impact of the dose,  $x_i$ , that the individual  $i$  received. To make priors easier to define and interpret, we subtracted the intermediate dose from the dose values, i.e., we set  $x^* = \log(48)$ . This adjustment implies that the parameter  $\alpha_i$  represents the expected total amount of virus shedding when the inoculum dose is at this intermediate value. (Without subtraction of  $x^*$ ,  $\alpha_i$  would represent total shedding if the dose was zero, which is biologically not meaningful and makes assigning reasonable priors more difficult (6).)

Priors are chosen based on what we know about the virus kinetics, and to ensure prior predictive simulations produce flexible but reasonable outcomes (6). We used Half-Cauchy



distributions for priors of standard deviation, because Cauchy has fatter tails than normal distribution which will make priors less informative. Since vomit outcome values were lower than those for feces, we adjusted the  $\alpha_i$  prior for this model to have a mean around 20.

As part of our sensitivity analyses, presented below, we also explored a model which treats dose as categorical. The following lines in the model are adjusted accordingly:

Linear model:

$$\mu_i = \alpha_i + \beta_{dose_i}$$

Adaptive priors:

$$\alpha_i \sim \text{Normal}(0, \gamma)$$

Fixed priors:

$$\gamma \sim \text{Half-Cauchy}(0, 2)$$

$$\beta_{dose_i} \sim \text{Normal}(25, 5),$$

In this notation, the parameter  $\beta_{dose_i}$  takes on discrete values based on the dose level of each individual,  $i$ . Specifically, the 3 categories are low, medium, or high dose, corresponding to 4.8, 48, or 4800 RT-PCR units.

### Modeling longitudinal virus concentration kinetics

To model the longitudinal time-series of virus concentration in feces, we used a previously developed equation that was shown to describe virus time-course in acute viral infections well (7). This equation provides a good empirical function to fit the increase, then decrease of viral load seen in many acute viral infections. The equation has four parameters and is given by:

$$V(t) = \frac{2p}{e^{-g(t-T)} + e^{d(t-T)}}$$

The outcome of interest is virus load as a function of time,  $V(t)$ . The model parameters approximately represent the peak virus load ( $p$ ), the initial exponential growth rate ( $g$ ), the time of virus peak ( $T$ ) and the eventual rate of virus decline ( $d$ ). (The parameters only approximately map to those biologic quantities, see (7) for details.)

Since all parameters in the model above need to be positive to achieve biologically reasonable trajectories for  $V(t)$ , we rewrote the equation for our purpose with exponentiated parameters. That is, we assume that the deterministic portion of the virus load data (on a log scale, denoted below as  $\mu_{i,t}$ ), is described for each individual,  $i$ , by

$$\mu_{i,t} = \log \left( \frac{2 \exp(p_i)}{e^{-\exp(g_i)(t_i - \exp(T_i))} + e^{\exp(d_i)(t_i - \exp(T_i))}} \right)$$

Since there was a fair amount of variability in the virus load data, we modeled the outcome using a non-standardized Student-t distribution instead of a Normal distribution, which provides more robust estimates in the presence of strong variability (2,6). Specifically, we model the virus load data as

$$y_{i,t} \sim \text{Student-t}(k, \mu_{i,t}, \sigma)$$

where the standard deviation ( $\sigma$ ) is modeled with a Half-Cauchy distribution, and the degrees of freedom ( $k$ ) are modeled with a Gamma distribution with priors as shown in the equations below. We assumed that each of the four model parameters of the  $\mu_{i,t}$  equation follow normal distributions, and can be described by linear models, each with an individual-level intercept parameter and a parameter quantifying the potential impact of dose. We again modeled the latter for our main analysis as being a linear function of the log of the dose. As described above, we again subtracted the intermediate dose to make the intercept parameters biologically meaningful. The model equations are given by:

Likelihood:

$$y_{i,t} \sim \text{Student}(k, \mu_{i,t}, \sigma)$$

Overall time-series equation:

$$\mu_{i,t} = \log\left(\frac{2\exp(p_i)}{e^{-\exp(g_i)(t_i - \exp(T_i))} + e^{\exp(d_i)(t_i - \exp(T_i))}}\right)$$

Parameter equations:

$$p_i = p_{0,i} + p_1 \cdot (x_i - x^*)$$

$$g_i = g_{0,i} + g_1 \cdot (x_i - x^*)$$

$$T_i = T_{0,i} + T_1 \cdot (x_i - x^*)$$

$$d_i = d_{0,i} + d_1 \cdot (x_i - x^*)$$

Adaptive priors:

$$p_{0,i} \sim \text{Normal}(\mu_p, \sigma_p)$$

$$g_{0,i} \sim \text{Normal}(\mu_g, \sigma_g)$$

$$T_{0,i} \sim \text{Normal}(\mu_T, \sigma_T)$$

$$d_{0,i} \sim \text{Normal}(\mu_d, \sigma_d)$$

Fixed priors:

$$\mu_p \sim \text{Normal}(25, 5)$$

$$\sigma_p \sim \text{Half-Cauchy}(0, 1)$$

$$\mu_g \sim \text{Normal}(3, 1)$$

$$\sigma_g \sim \text{Half-Cauchy}(0, 1)$$

$$\mu_T \sim \text{Normal}(0, 1)$$

$$\sigma_T \sim \text{Half-Cauchy}(0, 1)$$

$$\mu_d \sim \text{Normal}(-1, 0.5)$$

$$\sigma_d \sim \text{Half-Cauchy}(0, 1)$$

$$p_1 \sim \text{Normal}(0, 1)$$

$$g_1 \sim \text{Normal}(0, 0.5)$$

$$T_1 \sim \text{Normal}(0, 0.5)$$

$$d_1 \sim \text{Normal}(0, 0.5)$$

$$k \sim \text{Gamma}(\text{shape} = 2, \text{rate} = 0.1)$$

$$\sigma \sim \text{Half-Cauchy}(0, 1)$$

Values for priors were chosen to be weakly informative, such that prior predictive simulations produced virus-load trajectories that made biologic sense, while still allowing for a wide variety of possible trajectories to be informed by fitting to the data. The peak level of virus concentration for norovirus in our data and previous studies is broadly in the range of  $10^{10}$  to  $10^{14}$  (1,8,9) (around 23–35 in log units). We approximately centered our prior around those values, while allowing for a broad standard deviation so that the data will dominate the posterior results. Similarly, the growth rate,  $\mu_g$ , will have a value such that the peak is reached within the

first several days following infection. A Normal distribution with a mean of 3 (in log units) can produce the necessary range of value. Virus is expected to peak a few days following infection. Thus we chose  $\mu_T$  and  $T_1$  to have normal distributions with a spread such that the range of values for  $\exp(T)$  is centered around the first few days. The decay rate,  $\mu_d$ , needs to allow for a decline of virus to undetectable levels that can be as fast as a week or longer than a month. A Normal distribution with log-transformed mean of  $-1$  can produce such outcomes.

We performed prior predictive simulations to ensure that our priors led to biologically reasonable time-series trajectories, while also being broad and flexible enough to let the data dominate the posterior distribution.

For the sensitivity analysis, where we treated dose as a categorical variable, the dose-associated parameters change and now are assigned distinct values based on dose category. The following components of the above model changed, with the rest remaining the same:

Parameter equations:

$$p_i = p_{0,i} + p_{1,dose_i}$$

$$g_i = g_{0,i} + g_{1,dose_i}$$

$$T_i = T_{0,i} + T_{1,dose_i}$$

$$d_i = d_{0,i} + d_{1,dose_i}$$

Adaptive priors:

$$p_{0,i} \sim \text{Cauchy}(0, \gamma_p)$$

$$g_{0,i} \sim \text{Cauchy}(0, \gamma_g)$$

$$T_{0,i} \sim \text{Cauchy}(0, \gamma_T)$$

$$d_{0,i} \sim \text{Cauchy}(0, \gamma_d)$$

Fixed priors:

$$\gamma_p \sim \text{Half-Cauchy}(0,1)$$

$$\gamma_g \sim \text{Half-Cauchy}(0,1)$$

$$\gamma_T \sim \text{Half-Cauchy}(0,1)$$

$$\gamma_d \sim \text{Half-Cauchy}(0,1)$$

$$p_{1,dose_i} \sim \text{Normal}(25,5)$$

$$g_{1,dose_i} \sim \text{Normal}(3,1)$$

$$T_{1,dose_i} \sim \text{Normal}(0,1)$$

$$d_{1,dose_i} \sim \text{Normal}(-1,0.5)$$

As before, in this categorical analysis,  $x_i$  is the dose category for individual  $i$ , and is either low, medium or high.

## **Analysis of symptom outcomes**

The following sections provide additional details and further results related to our analyses of infection symptoms.

We considered three different symptom-related outcomes, namely time to first symptom onset (incubation period) and two versions of scores that quantify overall infection severity.

Since individuals were allowed to leave the study center after 96 hours and illness is typically self-limiting lasting for only a few days (10), we calculated the scores based on records in the first 4 days.

### **Incubation period**

Incubation period, i.e., the time between infection and onset of symptoms, was directly computed from the data as the time-span between reported time at which the infection challenge was administered, and the time at which the first symptom was reported.

### **Modified Vesikari score (MVS)**

The modified Vesikari score (MVS) is a previously defined quantity that has been used in a modified form by several studies to measure norovirus severity (11–14). The score has the seven components shown in Appendix Table 4. For our dataset, since volunteers were housed in a healthcare setting, the health care provider visit component was not applicable, and we thus removed it from the score calculation (13). Since we did not have information on treatment, we also dropped that component. This left us with a five-component score, which was computed for each individual following the rules shown in Appendix Table 4.

Appendix Table 5 shows the scores for all 20 volunteers in the study that were part of our analyses.

### **Comprehensive symptom score (CSS)**

In addition to the modified Vesikari score, we defined and computed a comprehensive symptom score which took all recorded symptoms into account.

The study reported the following symptoms: body temperature, malaise, muscle aches, headache, nausea, chills, anorexia, cramps, unformed or liquid feces, and vomiting. Clinical symptoms (except feces and vomiting) were reported as none, mild, moderate, or severe, which

we coded as a score of 0 to 3. For feces, we used a scoring of solid = 0, unformed = 1, and liquid = 2. Vomit was reported as absent or present and scored as 0 or 1.

Individuals had their symptoms recorded at different times and frequencies throughout the day. Thus, summing up the recorded scores would have introduced bias due to different recording frequencies. Thus, we instead determined the highest score per symptom for each individual per day, and summed those. This produced a daily total symptom score for each individual. We then summed those to obtain our comprehensive symptom score. For example, if one individual had daily total symptom score values of 5 (1st day), 10 (2nd day), 2 (3rd day), and 0 (4th day), the final total symptom scores would be 17.

Appendix Table 6 shows the daily and total comprehensive score values for the 20 individuals, Appendix Figure 1 shows the same information in graphical form, stratified by dose.

### Modeling symptom outcomes

Using following models, we tested the impact of dose on each kind of symptom in the trial and two types of symptom scores.

The incubation period is positive and not too far from zero (as measured in days). Thus, to prevent any possible negative outcomes, we assumed it followed a log-normal distribution. The rest of the model is similar to those implemented for the total shedding outcomes, with the full model is given below.

$$\begin{aligned}
 & \text{Likelihood:} \\
 & Y_i \sim \text{Log-Normal}(\mu_i, \sigma) \\
 & \text{Linear model:} \\
 & \mu_i = \alpha_i + \beta(x_i - x^*) \\
 \text{Adaptive priors:} & \\
 & \alpha_i \sim \text{Normal}(\delta, \gamma) \\
 \text{Fixed priors:} & \\
 & \delta \sim \text{Normal}(1,5) \\
 & \gamma \sim \text{Half-Cauchy}(0,2) \\
 & \beta \sim \text{Normal}(0,1) \\
 & \sigma \sim \text{Half-Cauchy}(0,2),
 \end{aligned}$$

As we did for the total shedding outcomes, the model was adjusted for the categorical dose sensitivity analysis as follows.

$$\begin{aligned}
& \text{Linear model:} \\
& \mu_i = \alpha_i + \beta_{dose_i} \\
\text{Adaptive priors:} \\
& \alpha \text{ prior: } \alpha_i \sim \text{Normal}(0, \gamma) \\
\text{Fixed priors:} \\
& \gamma \sim \text{Half-Cauchy}(0, 2) \\
& \beta_{dose_i} \sim \text{Normal}(1, 5)
\end{aligned}$$

We used the same overall model structure for the MSV and CSS outcomes. However, we modeled these outcomes using a Gamma-Poisson distribution (also called negative binomial distribution) for the likelihood, since both scores are nonnegative integer-valued. The Gamma-Poisson model allows for additional variance (also called overdispersion) compared to a Poisson distribution. The variance is determined by the  $\phi$  parameter, and the rate  $\lambda$  is similar to the rate of an ordinary Poisson distribution. We use the customary log-link for  $\lambda$ , and model its functional relationship with dose as above with an individual-level intercept and a dose-specific component, linearly dependent on the log of the dose. The model is given by the following set of equations.

$$\begin{aligned}
& \text{Likelihood:} \\
& y_i \sim \text{Gamma-Poisson}(\lambda_i, \phi) \\
& \text{Linear model:} \\
& \log(\lambda_i) = \alpha_i + \beta(x_i - x^*) \\
\text{Adaptive priors:} \\
& \alpha_i \sim \text{Normal}(\delta, \gamma) \\
\text{Fixed priors:} \\
& \delta \sim \text{Normal}(1, 5) \\
& \gamma \sim \text{Half-Cauchy}(0, 2) \\
& \beta \sim \text{Normal}(0, 1) \\
& \phi \sim \text{Half-Cauchy}(0, 2)
\end{aligned}$$

Values for the prior distributions were again chosen to ensure reasonable prior predictive results for the outcomes. To model dose as a categorical variable, we changed the following parts of the model.

$$\begin{aligned} & \text{Linear model:} \\ & \log(\lambda_i) = \alpha_i + \beta_{dose_i} \\ \text{Adaptive priors:} & \\ & \alpha_i \sim \text{Normal}(0, \gamma) \\ \text{Fixed priors:} & \\ & \gamma \sim \text{Half-Cauchy}(0, 2) \\ & \beta_{dose_i} \sim \text{Normal}(1, 5) \end{aligned}$$

## Model setup, outcomes and diagnostics

In our Bayesian models, we generally implemented four chains with  $\approx 30k$  iterations with 25k as a warmup to obtain 5k posterior samples for final results. We assessed Rhat, mixing of chains, and posterior distributions to ensure convergence.

As described above, the models were implemented in R using the brms package. We report results based on predictions from the posterior samples of the models (3). The predictions are based on an assumption that a new individual, who theoretically similar to individuals in this trial but has not been enrolled previously, be given with a certain amount of virus. Then, the model posterior predictive distribution of the new individual was summarized by a mean and credible interval for an outcome.

## Evaluation of prior and posterior distributions for model parameters

To ensure that our results were not overly influenced by the choice of prior distributions, we compared prior and posterior distributions.

The parameter's prior and posterior distributions showed that the choice of prior distribution had no significant impact on our results (Appendix Figure 2 to 4).

## Results from additional analyses

### Fecal virus shedding during the full observation period

In the main text, we focus on the data collected during the time individuals were under direct observation, since this ensures complete collection of all feces. Here, we investigate the relation between dose and total fecal shedding for all samples, including those individuals were



asked to collect after returning home. We did not find evidence for associations between dose and virus shedding.

### **Impact of changing assumption for LOD values**

As described above, for the non time-series analysis shown in the main text, we set measurements that were below LOD2 but above LOD1 to the geometric mean of those 2 values, and values below LOD1 were set to the geometric mean of LOD1 and 1. To explore the impact of these choices, we tested a few different choices for those values. The next figures show that the overall observed pattern remains consistent, independent of the choices for the LOD values.

### **Vomit events**

In each dose group, only a few individuals had vomiting events. Some of these individuals had multiple vomiting events. Appendix Figure 8 graphically displays the vomiting event data. The recorded vomiting events were not sufficient to allow for a time-series analysis.

### **Individual-level fits to fecal sheedding time series data**

The longitudinal virus shedding data in feces and fitted model results are shown in Appendix Figure 9 for each individual.

### **Correlation between total virus shed in feces and virus load**

We compared the fitted total virus load (area under the curve), to the observed total virus shed in feces to assess model performance. We found strong correlation, which support the robustness of our models.

### **Assessing association of individual symptoms with dose**

In the main text, we show that there is little association between dose and symptoms if quantified by the MVS, but there is an association if quantified by the CSS. To understand this difference, we explored correlations between all individual symptoms and dose. While the uncertainty intervals are wide, the figure below shows that symptoms that are part of the MVS (Feces form, Body temperature, and Vomit) show very little variation with dose, while a few other symptoms, which are part of CSS but not MVS, do show some dose variation (Cramps, Malaise and Nausea). This is likely the reason why CSS shows variation with dose, while MVS does not. A similar pattern is seen when dose is treated categorically, as shown below.

### **Assessing association of symptoms with virus growth rate**

In the discussion, we speculate that the association of dose with increased symptoms might be mediated by a more rapid onset of the disease, due to more rapid initial virus growth at higher doses. To test this, we used the fitted individual level virus load curves and calculated the virus growth rate by

$$g_v = \frac{v_{t=0.625} - v_{t=0.5}}{0.625 - 0.5},$$

where,  $g_v$  is virus concentration growth rate;  $v_{t=0.625}$  is the virus concentration value at day 0.625;  $v_{t=0.5}$  is the time of virus concentration at day 0.5. We arbitrarily chose the two time points to make sure the virus concentration is in the exponential growth phase and has not yet started to level off.

The following figures show the association between growth rate and symptom scores (MVS and CSS) for each individual. They are nonlinear curves because negative binomial distributions were used in models similarly to the symptom scores (Appendix Figure 4, main manuscript). The range of x-axis was based on data.

### **Treating dose as a categorical variable**

The following figures repeat the analyses and results shown in the main text, but now with dose treated as categorical.

### **Assessing association of total virus shedding with dose**

Appendix Figure 14 shows data and model estimates for total shedding for each dose category, where low/medium/high indicate dose levels of 4.8, 48, and 4800 RT-PCR units. The overall pattern is similar to the one we found for the continuous analysis presented in the main text.

### **Modeling of virus concentration in feces**

Appendix Figures 15 – 17 show data and model estimates for the longitudinal time-series analysis of the virus concentration in feces, with dose now treated as categorical (low, medium, or high). Again, the overall observed patterns are similar to the ones we found for the continuous analysis presented in the main text.

### **Assessing association of symptoms with dose**

Appendix Figure 18 shows data and model estimates for the different symptom outcomes for each dose category. Again, the patterns seen are similar to those shown in the main text. One difference is that the comprehensive score only increases for the highest dose group, while the two lower groups are similar.

Looking at 95% credible interval of each symptom's score (horizontal bars in Appendix Figure 19) by 3 dose groups, we again find the pattern reported above for the case of treating dose as continuous. Namely, symptoms associated with MVS do not show any pronounced variation with dose, while several symptoms that are part of the CSS but not the MVS do show variation with dose.

### **Analyses with inclusion of the very-low dose infected individual**

As explained in the main text, the original study also administered a dose of 0.48 RT-PCR units. At that dose level, only a single challenged individual became infected. We removed this person for the analysis presented in the main text. However, we also decided to conduct a sensitivity analysis that re-computes all results shown in the main text, now with the additional individual included.

### **Assessing association of total virus shedding with dose**

Comparison of this figure with the one shown in the main text shows overall similar results.

### **Modeling of virus concentration in feces**

As Appendix Figures 21 – 23 show, the findings remain essentially unchanged for these outcomes compared to what is shown in the main text.

### **Assessing association of symptoms with dose**

As Appendix Figure 24 shows, the association between dose and symptom outcomes also remains essentially unchanged when including the additional individual in the analysis. We also again find a similar pattern between individual symptoms and dose as found previously (Appendix Figure 25).

## References

1. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Norwalk virus shedding after experimental human infection. *Emerg Infect Dis.* 2008;14:1553–7. [PubMed](#)  
<https://doi.org/10.3201/eid1410.080117>
2. Bürkner P-C. Advanced Bayesian multilevel modeling with the R Package brms. *R J.* 2018;10:395.  
<https://doi.org/10.32614/RJ-2018-017>
3. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. *Bayesian data analysis.* 3rd edition. Boca Raton: CRC Press; 2013.
4. Gilpatrick SG, Schwab KJ, Estes MK, Atmar RL. Development of an immunomagnetic capture reverse transcription-PCR assay for the detection of Norwalk virus. *J Virol Methods.* 2000;90:69–78.  
[PubMed](#) [https://doi.org/10.1016/S0166-0934\(00\)00220-2](https://doi.org/10.1016/S0166-0934(00)00220-2)
5. Kirby AE, Streby A, Moe CL. Vomiting as a symptom and transmission risk in norovirus illness: evidence from human challenge studies. *PLoS One.* 2016;11:e0143759. [PubMed](#)  
<https://doi.org/10.1371/journal.pone.0143759>
6. McElreath R. *Statistical rethinking: a Bayesian course with examples in R and Stan.* 2nd edition. Boca Raton: Taylor and Francis, CRC Press; 2020.
7. Holder BP, Beauchemin CA. Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture. *BMC Public Health.* 2011;11(Suppl 1):S10. [PubMed](#)  
<https://doi.org/10.1186/1471-2458-11-S1-S10>
8. Lee N, Chan MCW, Wong B, Choi KW, Sin W, Lui G, et al. Fecal viral concentration and diarrhea in norovirus gastroenteritis. *Emerg Infect Dis.* 2007;13:1399–401. [PubMed](#)  
<https://doi.org/10.3201/eid1309.061535>
9. Teunis PFM, Sukhrie FHA, Vennema H, Bogerman J, Beersma MFC, Koopmans MPG. Shedding of norovirus in symptomatic and asymptomatic infections. *Epidemiol Infect.* 2015;143:1710–7.  
**PMID 25336060**
10. Matthews JE, Dickey BW, Miller RD, Felzer JR, Dawson BP, Lee AS, et al. The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup. *Epidemiol Infect.* 2012;140:1161–72. [PubMed](#) <https://doi.org/10.1017/S0950268812000234>
11. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scand J Infect Dis.* 1990;22:259–67. [PubMed](#)  
<https://doi.org/10.3109/00365549009027046>

12. Freedman SB, Eltorky M, Gorelick M; Pediatric Emergency Research Canada Gastroenteritis Study Group. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics*. 2010;125:e1278–85. [PubMed https://doi.org/10.1542/peds.2009-3270](https://doi.org/10.1542/peds.2009-3270)
13. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk virus illness. *N Engl J Med*. 2011;365:2178–87. [PubMed https://doi.org/10.1056/NEJMoa1101245](https://doi.org/10.1056/NEJMoa1101245)
14. Bierhoff M, Arvelo W, Estevez A, Bryan J, McCracken JP, López MR, et al. Incidence and clinical profile of norovirus disease in Guatemala, 2008–2013. *Clin Infect Dis*. 2018;67:430–6. [PubMed https://doi.org/10.1093/cid/ciy091](https://doi.org/10.1093/cid/ciy091)

**Appendix Table 1.** Description of norodata.Rds

Files	Notes
data_tab1	Data description
feces96	Virus shedding in feces (96 h)
fvshed_gmu_96h_LOD12_0_15000	Virus shedding in feces (96 h) low limit for LODs
fvshed_gmu_96h_LOD12_0_4e7	Virus shedding in feces (96 h) up limit for LODs
fecesall	Virus shedding in feces (all)
vomit	Virus shedding in vomit (all)
ftsshedding	Time-series virus shedding in feces
vtsshedding	Time-series virus shedding in vomit
incubation	Onset of symptoms (Incubation)
css_10symptoms	Comprehensive symptom score components (CSSC)
css	Comprehensive symptom score (CSS)
mvs	Modified Vesikari score (MVS)

**Appendix Table 2.** Description of four variables

NO.	Variable	Notes
1	ID	Individual ID
2	dose	Amount of dose (RT-PCR unit)
3	dose_cat	Amount of dose (categorical version)
4	dose_log	Dose variable used in models ( $\log(\text{Amount of dose}) - \log(48)$ )

**Appendix Table 3.** Description of variables necessary for later time-series modeling

NO.	Variable	Notes
1	y_censor	Indicator of censoring due to LOD, 0 = no censoring, 2 = interval censoring
2	y_virus	Observed virus in the feces
3	yc	Lower bound of the interval censoring
4	logy	Natural log of the observed virus in the feces
5	logyc	Natural log of the lower bound of the interval censoring

**Appendix Table 4.** Modified vesikari score components


Components	Score = 0	Score = 1	Score = 2	Score = 3
C1: Diarrhea duration, days	0	1 - 4	5	> = 6
C2: Maximum number of daily diarrheal stools	0	1 - 3	4 - 5	> = 6
C3: Vomiting duration, days	0	1	2	> = 3
C4: Maximum number of daily vomiting episodes	0	1	2 - 4	> = 5
C5: Maximum recorded fever	Not Elevated	Moderate	Mild	Severe
Health care provider visits	N/A	N/A	N/A	N/A
Treatment	N/A	N/A	N/A	N/A

**Appendix Table 5.** Modified vesikari scores for each individual.


ID	Dose	C1	C2	C3	C4	C5	Total
ID1	4800	0	0	1	2	0	3
ID2	4800	0	0	0	0	0	0
ID3	4800	0	0	0	0	1	1
ID4	4800	1	1	0	0	0	2
ID5	4800	1	2	1	2	2	8
ID6	4800	1	1	2	2	0	6
ID7	48	1	1	0	0	0	2
ID8	48	1	1	0	0	0	2
ID9	48	0	0	0	0	1	1
ID10	48	1	1	1	2	2	7
ID11	48	0	0	1	2	1	4
ID12	48	1	1	1	2	0	5
ID13	48	0	0	1	2	0	3
ID14	4.8	1	1	1	2	0	5
ID15	4.8	0	0	1	2	0	3
ID16	4.8	0	0	1	2	1	4
ID17	4.8	1	1	1	2	0	5
ID18	4.8	0	0	0	0	0	0
ID19	4.8	0	0	0	0	0	0
ID20	0.48	0	0	1	2	0	3

**Appendix Table 6.** Comprehensive symptom score values.

ID	Dose	Day1	Day2	Day3	Day4	Total
ID1	4800	1	7	2	0	10
ID2	4800	1	7	5	0	13
ID3	4800	0	6	13	2	21
ID4	4800	0	9	9	0	18
ID5	4800	1	14	15	3	33
ID6	4800	7	8	8	0	23
ID7	48	1	5	2	0	8
ID8	48	1	2	7	3	13
ID9	48	0	0	2	0	2
ID10	48	1	14	2	0	17
ID11	48	1	9	2	0	12
ID12	48	0	9	0	0	9
ID13	48	0	10	0	0	10
ID14	4.8	0	10	2	0	12
ID15	4.8	1	1	12	3	17
ID16	4.8	0	8	4	0	12
ID17	4.8	4	4	8	0	16
ID18	4.8	0	1	1	1	3
ID19	4.8	0	2	3	0	5
ID20	0.48	2	7	3	0	12




**Appendix Figure 1.** Daily comprehensive symptom score stratified by inoculum dose group




**Appendix Figure 2.** Comparisons of parameters' prior and posterior distributions for the main model.







**Appendix Figure 3.** Comparisons of parameters' prior and posterior distributions for the model with one the very-low dose infected individual.




**Appendix Figure 4.** Comparisons of parameters' prior and posterior distributions for the model dose as a categorical variable.




**Appendix Figure 5.** Virus shedding in feces during the full observation period. Everything else as described for main text Appendix Figure 1.




**Appendix Figure 6.** The association between dose and virus shedding in feces (first 4 days) when values below the LOD1 were set to 1, and values between LOD1 and LOD2 were set to 15000 (the LOD1 value).




**Appendix Figure 7.** The association between dose and virus shedding in feces (first 4 days) when values below the LOD1 were set to 1, and values between LOD1 and LOD2 were set to  $4 \times 10^7$  (the LOD2 value).




**Appendix Figure 8.** Vomiting events and virus concentration for each event, stratified by dose. Symbols indicate different individuals. 4, 3 and 3 individuals had at least one vomiting event in the low/medium/high dose groups respectively.




**Appendix Figure 9.** Fitted fecal virus concentration curves. The red lines show mean of estimations. The gray areas show 95% equal-tailed credible interval (CI). LOD1 and LOD2 indicate the two limits of detection. Points with triangle shape represented samples that are positive qRT-PCR. Points with circle shape represented samples that are positive IMC and negative qRT-PCR. Points with square shape represented samples that are negative IMC and negative qRT-PCR. Data are shown as originally reported, values below either of the LODs were treated during model fitting as described above.




**Appendix Figure 10.** Correlation plot between total virus shed in feces and virus load. Open circles represent data points. The lines and shaded regions indicate the mean and 95% credible intervals of the fitted Bayesian model.



**Appendix Figure 11.** Associations between dose and each type of symptoms used for the calculation of comprehensive symptom score. The impact of dose was tested with each kind of symptom in the CSS.




**Appendix Figure 12.** Associations between CSS and virus growth rate estimated by the time series model.




**Appendix Figure 13.** Associations between MVS and virus growth rate estimated by the time series model.







**Appendix Figure 14.** Virus shedding in feces or vomit. The bars show 95% equal-tailed credible intervals (CI). Points with circle shape are raw data. A) Fecal virus shedding in the first 96 hours. B) Fecal virus shedding with all data. C) Vomit virus shedding. The points show mean of estimations. Missing values due to LODs were replaced with fixed values (Supplementary, accounting for limits of detection).




**Appendix Figure 15.** Fitted fecal virus concentration curves. The red lines show means of estimations. The gray areas show 95% equal-tailed credible intervals (CI). LOD1 and LOD2 indicate the two limits of detection. Points with triangle shape represented samples that with positive qRT-PCR results. Points with circle shape represented samples with positive IMC and negative qRT-PCR results. Points with square shape represented samples with negative IMC and negative qRT-PCR results. Missing values due to LODs were treated as censors (Supplementary accounting for limits of detection).




**Appendix Figure 16.** Fitted virus concentration (GEC/g) in feces. The lines show means of estimations. The colored areas show 95% equal-tailed credible intervals (CI). LOD1 and LOD2 represent the two limits of detection. A) The fitted curves for 90 days. B) The fitted curves for the first 7 days. Missing values due to LODs were treated as censors (Supplementary accounting for limits of detection).




**Appendix Figure 17.** Model predictions for viral kinetics as a function of inoculum dose. The points show means of estimations. The bars show 95% equal-tailed credible intervals (CI). A) Time to detection (above 15,000 GEC). B) Time to peak. C) Shedding duration (period that virus concentration above 15,000 GEC). D) Total virus load (area under concentration curve).




**Appendix Figure 18.** Estimated dose impact on symptoms. The points show means of estimations. The bars show 95% equal-tailed credible intervals (CI). Points with circle shape are raw data.




**Appendix Figure 19.** Associations between dose and each type of symptoms used for the calculation of comprehensive symptom score. The impact of dose was tested with each kind of symptom in the CSS.



**Appendix Figure 20.** Virus shedding in feces or vomit. A) Total fecal virus shedding in the first 96 hours. B) Total fecal virus shedding with all data. C) Total vomit virus shedding. The lines show means of estimations. The gray areas show 95% equal-tailed credible intervals (CI). Points with circle shape are raw data. Missing values due to LODs were replaced with fixed values (Supplementary, accounting for limits of detection).




**Appendix Figure 21.** Fitted fecal virus concentration curves. The red lines show means of estimations. The gray areas show 95% equal-tailed credible intervals (CI). LOD1 and LOD2 indicate the two limits of detection. Points with triangle shape represent samples that are positive for qRT-PCR. Points with circle shape represented samples that are positive for IMC and negative for qRT-PCR. Points with square shape represented samples that are negative for IMC and negative for qRT-PCR. Missing values due to LODs were treated as censors (Supplementary accounting for limits of detection).




**Appendix Figure 22.** Fitted virus concentration (GEC/g) in feces. The lines show means of estimations. The colored areas show 95% equal-tailed credible intervals (CI). LOD1 and LOD2 represent the two limits of detection. A) The fitted curves for 90 days. B) The fitted curves for the first 7 days. Missing values due to LODs were treated as censors (Supplementary accounting for limits of detection).






**Appendix Figure 23.** Model predictions for viral kinetics as a function of inoculum dose. The lines show means of estimations. The gray areas show 95% equal-tailed credible intervals (CI). A) Time to detection (above 15,000 GEC). B) Time to peak. C) Shedding duration (period that virus concentration above 15,000 GEC). D) Total virus load (area under curve).



**Appendix Figure 24.** Estimated dose impact on symptoms. The lines show means of estimations. The gray areas show 95% equal-tailed credible intervals (CI). Points with circle shape are raw data.



**Appendix Figure 25.** Associations between dose and each type of symptoms used for the calculation of comprehensive symptom score. The impact of dose was tested with each kind of symptom in the CSS.